BioMarin Pharmaceutical Inc. Files Definitive Proxy Statement

Ticker: BMRN · Form: DEF 14A · Filed: Apr 9, 2024 · CIK: 1048477

Biomarin Pharmaceutical INC DEF 14A Filing Summary
FieldDetail
CompanyBiomarin Pharmaceutical INC (BMRN)
Form TypeDEF 14A
Filed DateApr 9, 2024
Risk Levellow
Pages15
Reading Time18 min
Key Dollar Amounts$2.42 b, $469.9 million, $169.1 million, $2.4 billion
Sentimentneutral

Sentiment: neutral

Topics: Proxy Statement, DEF 14A, BioMarin Pharmaceutical, Executive Compensation, Shareholder Meeting

TL;DR

<b>BioMarin Pharmaceutical Inc. has filed its Definitive Proxy Statement for the period ending May 21, 2024, detailing executive compensation and corporate governance matters.</b>

AI Summary

BIOMARIN PHARMACEUTICAL INC (BMRN) filed a Proxy Statement (DEF 14A) with the SEC on April 9, 2024. BioMarin Pharmaceutical Inc. filed a Definitive Proxy Statement (DEF 14A) on April 9, 2024. The filing covers the period ending May 21, 2024. The company's principal executive offices are located at 105 Digital Drive, Novato, CA 94949. The filing includes information related to executive compensation for the fiscal year ending December 31, 2023. Key individuals mentioned in relation to compensation data include Jean-Jacques Bienaimé and Alexander Hardy.

Why It Matters

For investors and stakeholders tracking BIOMARIN PHARMACEUTICAL INC, this filing contains several important signals. This DEF 14A filing is crucial for shareholders as it outlines proposals to be voted on at the annual meeting, including the election of directors and executive compensation plans. Shareholders can review the compensation details for key executives like Jean-Jacques Bienaimé and Alexander Hardy, providing transparency into how the company incentivizes its leadership.

Risk Assessment

Risk Level: low — BIOMARIN PHARMACEUTICAL INC shows low risk based on this filing. The filing is a routine DEF 14A, indicating standard corporate governance and shareholder communication procedures rather than immediate financial or operational concerns.

Analyst Insight

Shareholders should review the proxy statement to understand executive compensation, director nominations, and other proposals before the upcoming annual meeting.

Executive Compensation

NameTitleTotal Compensation
Jean-Jacques BienaiméMember
Alexander HardyMember

Key Numbers

Key Players & Entities

FAQ

When did BIOMARIN PHARMACEUTICAL INC file this DEF 14A?

BIOMARIN PHARMACEUTICAL INC filed this Proxy Statement (DEF 14A) with the SEC on April 9, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by BIOMARIN PHARMACEUTICAL INC (BMRN).

Where can I read the original DEF 14A filing from BIOMARIN PHARMACEUTICAL INC?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by BIOMARIN PHARMACEUTICAL INC.

What are the key takeaways from BIOMARIN PHARMACEUTICAL INC's DEF 14A?

BIOMARIN PHARMACEUTICAL INC filed this DEF 14A on April 9, 2024. Key takeaways: BioMarin Pharmaceutical Inc. filed a Definitive Proxy Statement (DEF 14A) on April 9, 2024.. The filing covers the period ending May 21, 2024.. The company's principal executive offices are located at 105 Digital Drive, Novato, CA 94949..

Is BIOMARIN PHARMACEUTICAL INC a risky investment based on this filing?

Based on this DEF 14A, BIOMARIN PHARMACEUTICAL INC presents a relatively low-risk profile. The filing is a routine DEF 14A, indicating standard corporate governance and shareholder communication procedures rather than immediate financial or operational concerns.

What should investors do after reading BIOMARIN PHARMACEUTICAL INC's DEF 14A?

Shareholders should review the proxy statement to understand executive compensation, director nominations, and other proposals before the upcoming annual meeting. The overall sentiment from this filing is neutral.

How does BIOMARIN PHARMACEUTICAL INC compare to its industry peers?

BioMarin Pharmaceutical Inc. operates in the pharmaceutical preparations industry, focusing on rare genetic diseases.

Are there regulatory concerns for BIOMARIN PHARMACEUTICAL INC?

The filing is made under the Securities Exchange Act of 1934, specifically Section 14(a), which governs the solicitation of proxies.

Industry Context

BioMarin Pharmaceutical Inc. operates in the pharmaceutical preparations industry, focusing on rare genetic diseases.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, specifically Section 14(a), which governs the solicitation of proxies.

What Investors Should Do

  1. Review the detailed executive compensation breakdown for 2023.
  2. Understand the proposals to be voted on at the upcoming shareholder meeting.
  3. Assess director nominations and corporate governance policies outlined in the filing.

Key Dates

Year-Over-Year Comparison

This is the initial filing of the DEF 14A for the 2024 proxy season, detailing information relevant to the upcoming shareholder meeting.

Filing Stats: 4,482 words · 18 min read · ~15 pages · Grade level 13.6 · Accepted 2024-04-09 16:07:24

Key Financial Figures

Filing Documents

Executive Compensation

Executive Compensation 62 Compensation Discussion and Analysis 62

Executive Compensation Tables

Executive Compensation Tables 92 Stock Ownership Information 112

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 112 Director and Officer Stock Ownership Guidelines 113 Anti-Hedging and Anti-Pledging Policy 115 Delinquent Section 16(a) Reports 115 Equity Compensation Plan Information 115 Additional Information 116 Questions and Answers about these Proxy Materials and Voting 116 Householding of Proxy Materials 123 Other Matters 123 Special Note Regarding Forward-Looking Statements 124 2 2024 Proxy Statement Letter from the Chair of Our Board of Directors Dear BioMarin Stockholders, On behalf of the Board of Directors, I'd like to thank you for your investment in BioMarin. Last year was an important time in the evolution of the company, as we continued on our journey to reach more patients with rare genetic conditions around the world. BioMarin reported strong growth, with revenue reaching $2.42 billion, an increase of 15% from 2022, and earnings per share continuing to grow. The growth was driven by the strength of VOXZOGO for children with achondroplasia, as well as the company's base enzyme replacement therapy business. BioMarin also received FDA approval for ROCTAVIAN, the world's first gene therapy for severe hemophilia A. Finally, we made important organizational changes, both to our management team and Board of Directors. In December, long-time Chairman and Chief Executive Officer, Jean-Jacques Bienaim retired, and we welcomed Alexander Hardy as President and Chief Executive Officer and a member of the Board, as part of a multi-year succession planning process and following a comprehensive search. I want to express my gratitude to JJ, whose vision and leadership transformed BioMarin from an unprofitable startup to a fully integrated, profitable biopharmaceutical company. The Board selected Alexander as the ideal leader to steer BioMarin through its next wave of growth. Alexander brings more than 30 years of experience in the global healthcare and biotechnology industries, s

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing